By SmashMeals Editorial — 2026-09-14 — Health & Nutrition
KINGSPORT, Tenn., Sept. 14, 2026 — On August 28, 2026, the FDA approved a new indication for Mounjaro (tirzepatide): reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with type 2 diabetes who are at high cardiovascular risk. It's the drug's first approval built specifically around heart outcomes, not just blood sugar or weight.
Educational only — not medical advice. SmashMeals is a food company, not a medical provider, and is not affiliated with, endorsed by, or sponsored by Eli Lilly. Follow your prescriber's guidance on medication decisions.
What the trial actually showed
The approval rests on SURPASS-CVOT, a randomized, double-blind trial that enrolled more than 13,000 people with type 2 diabetes and established atherosclerotic cardiovascular disease across 640 sites in 30 countries, followed for a median of roughly four years. Tirzepatide was compared head-to-head with dulaglutide (Trulicity), a GLP-1 already known to help the heart — and people on tirzepatide had an 8% lower relative risk of major cardiovascular events.
That's a meaningful result, and it's also a narrow one: it applies to adults with type 2 diabetes at high cardiovascular risk, compared against another active drug, not a placebo. It doesn't change what a person on Mounjaro should eat day to day.
The nutrition side doesn't move
A cardiovascular approval is genuinely good news for a specific group of patients. It isn't a nutrition finding. Appetite still drops on tirzepatide, digestion still slows, and the practical eating challenge — getting enough protein into fewer, smaller meals — is exactly the same one GLP-1 users have been managing since these drugs first launched for weight loss.
"An approval like this is good news for patients, but it doesn't change what's on their plate," said Lew Kizer, founder of SmashMeals. "Smaller appetite still means every bite has to carry more protein — that part of the equation hasn't moved."
Where SmashMeals fits
SmashMeals builds protein-forward entrées (protein that varies by meal, posted on every label) in a 100% dedicated gluten-free kitchen in Kingsport, TN, operating since 2017. Meals ship $30 flat-rate FedEx Ground to eligible addresses, with free Tri-Cities pickup and $15 local delivery. No subscription is required. None of this treats or prevents cardiovascular disease — that's between a patient and their prescriber. It's a practical answer to the same question this news raises: what do I actually eat on a smaller appetite?
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.